查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1579371

神经性厌食症市场：按治疗类型、年龄层、严重程度、最终用户、治疗管道 - 2025-2030 年全球预测

Anorexia Nervosa Market by Treatment Type (Nutritional Counseling, Pharmacotherapy, Psychotherapy), Age Group (Adults, Children & Adolescents), Severity Level, End User, Treatment Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年神经性厌食症市值为9,465万美元，预计2024年将达到1.0687亿美元，复合年增长率为13.27%，到2030年将达到2.2652亿美元。

神经性厌食症是一种严重的饮食障碍，其特征是对体重增加的强烈恐惧和扭曲的身体形象，导致饮食限制和过度减肥。解决神经性厌食症的必要性源自于其严重的健康影响，包括营养不良、心臟问题，甚至死亡。该领域的市场研究应用包括了解患者人口统计、医疗保健方法和治疗方式，最终用途范围包括医疗保健提供者、心理健康专业人员和药物。关键的成长要素是对心理健康问题的认识提高、治疗性介入的进步以及对医疗保健法规的支持。潜在的商机在于扩展用于远端患者监护的远距远端医疗服务、有效剂量的药物开发以及使用人工智慧和资料分析的个人化治疗计划。然而，市场成长面临许多限制，例如心理健康的社会耻辱、治疗成本高昂以及缺乏训练有素的专业人员等。物流限制和监管障碍使市场动态更加复杂。

主要市场统计
基准年[2023] 9465万美元
预测年份 [2024] 10687万美元
预测年份 [2030] 22652万美元
复合年增长率（%） 13.27%

为了利用这些机会，公司正在创新数位健康平台以提供持续的支持和治疗，探索非传统的整体治疗方法，例如正念和营养精神病学，我们应该专注于与健康倡导团体合作。此外，行动医疗技术可以针对年轻人进行早期疗育和提高意识。市场的本质是动态的、竞争性的，并且要求全面且易于获得的治疗解决方案。企业应加强对影响神经性厌食症的遗传因素的研究，这将大大促进个人化医疗。与高科技公司建立策略伙伴关係，开发穿戴式科技等先进诊断工具，可提供即时健康监测，进而改善患者的治疗效果和参与度。总体而言，坚实的市场策略和先进技术的结合可以为抓住市场机会和克服现有挑战做出重大贡献。

市场动态：快速发展的神经性厌食症市场的关键市场洞察

供需的动态交互作用正在改变神经性厌食症市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 扩大线上和数位疗法在治疗神经性厌食症患者中的作用
    • 政府对心理健康研究和治疗计划的承诺和资助
    • 整合营养师、心理学家和医生等多学科方法，为患者照护
  • 市场限制因素
    • 对神经性厌食症的高度耻辱和缺乏认识阻碍了早期诊断和早期疗育
  • 市场机会
    • 利用人工智慧改善神经性厌食症的早期检测与诊断
    • 制定有针对性的营养计划以支持神经性厌食症患者的康復
  • 市场挑战
    • 神经性厌食症的有效治疗方案有限阻碍了广泛康復

波特的五力：驾驭神经性厌食症市场的策略工具

波特的五力框架是了解神经性厌食症市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解神经性厌食症市场的外部影响

外部宏观环境因素在塑造神经性厌食症市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解神经性厌食症市场的竞争格局

对神经性厌食症市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵神经性厌食症市场供应商的绩效评估

FPNV定位矩阵是评估神经性厌食症市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製神经性厌食症市场的成功之路

对于想要加强在全球市场的影响力的公司来说，对神经性厌食症市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 线上和数位疗法在神经性厌食症患者治疗中的作用不断扩大
      • 政府对心理健康研究和治疗计划的承诺和资助
      • 整合营养师、心理学家和医生等多学科方法，提供全面的患者照护
    • 抑制因素
      • 对神经性厌食症的高度耻辱和缺乏认识阻碍了早期诊断和干预
    • 机会
      • 利用人工智慧改善神经性厌食症的早期检测与诊断
      • 制定有针对性的营养计划以支持神经性厌食症患者的康復
    • 任务
      • 神经性厌食症的有效治疗方案有限，阻碍了广泛的復原。
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章神经性厌食症市场治疗类型

  • 营养咨询
  • 药物治疗
    • 抗忧郁症
    • 抗精神病药
    • 情绪稳定剂
  • 心理治疗
    • 认知行为疗法
    • 家庭治疗
    • 人际心理治疗

第七章神经性厌食症市场：依年龄组

  • 成人
  • 儿童和青少年

第 8 章以严重程度分類的神经性厌食症市场

  • 温和的
  • 适度
  • 严重

第 9 章 神经性厌食症市场：依最终使用者分类

  • 诊所
  • 居家护理
  • 医院

第十章 神经性厌食症市场治疗管道

  • 住院病人
  • 门诊病人

第十一章美洲神经性厌食症市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太神经性厌食症市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东与非洲神经性厌食症市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 一项耗资 270 万欧元的新研究倡议旨在调查饮食障碍、自残和自闭症之间的联繫，并改善年轻人的早期诊断和介入。
    • Equip 获得额外资金以扩大虚拟饮食障碍治疗服务
    • 加州大学圣地牙哥分校已捐赠 235,000 美元开始一项临床试验，以测试酮疗法预防復发的有效性。
  • 战略分析和建议
    • 默克公司

公司名单

  • Alkermes plc
  • Amgen Inc.
  • Biohaven Pharmaceuticals
  • Hologic, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mindstrong Health
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • PsychoGenics Inc.
  • Sanofi SA
  • Sumitomo Pharma America, Inc.
  • Takeda Pharmaceutical Company Limited.
  • Tonix Pharmaceuticals Holding Corp.
Product Code: MRR-1A1A064C0422

The Anorexia Nervosa Market was valued at USD 94.65 million in 2023, expected to reach USD 106.87 million in 2024, and is projected to grow at a CAGR of 13.27%, to USD 226.52 million by 2030.

Anorexia Nervosa is a severe eating disorder characterized by an intense fear of gaining weight and a distorted body image, leading to restricted food intake and excessive weight loss. The necessity of addressing Anorexia Nervosa arises from its serious health implications, including malnutrition, heart issues, and even mortality. Application of market research in this domain includes understanding patient demographics, healthcare approaches, and treatment methodologies, while the end-use scope involves healthcare providers, mental health professionals, and pharmaceuticals. Key growth factors are the increasing awareness of mental health issues, advancements in therapeutic interventions, and supportive healthcare regulations. The potential opportunities lie in expanding telemedicine services for remote patient monitoring, pharmaceutical developments in effective medication, and personalized treatment plans leveraging AI and data analytics. However, the market growth faces limitations such as social stigma attached to mental health, high treatment costs, and a shortage of trained professionals. Logistical limitations and regulatory hurdles further complicate market dynamics.

KEY MARKET STATISTICS
Base Year [2023] USD 94.65 million
Estimated Year [2024] USD 106.87 million
Forecast Year [2030] USD 226.52 million
CAGR (%) 13.27%

To tap into these opportunities, businesses should focus on innovations in digital health platforms for continuous support and therapy, research into non-traditional and holistic treatment approaches like mindfulness and nutritional psychiatry, and collaborations with mental health advocacy groups. Additionally, mobile health technologies can target early-stage intervention and awareness among younger populations. The nature of the market is dynamic, with increasing competition and the need for comprehensive and accessible treatment solutions. Companies should enhance research on genetic factors impacting Anorexia Nervosa, contributing significantly to personalized medicine. Developing strategic partnerships with tech firms for advanced diagnostic tools like wearable technology can offer real-time health monitoring, thereby improving patient outcomes and engagement. Overall, integrating robust market strategies with advanced technology could significantly contribute to capturing market opportunities and overcoming existing challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anorexia Nervosa Market

The Anorexia Nervosa Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expanding role of online and digital therapies in treating patients with Anorexia Nervosa
    • Government initiatives and funding for mental health research and treatment programs
    • Integration of multidisciplinary approaches involving nutritionists, psychologists, and medical doctors for comprehensive patient care
  • Market Restraints
    • High stigma and lack of awareness surrounding anorexia nervosa impede early diagnosis and intervention
  • Market Opportunities
    • Leveraging artificial intelligence to improve early detection and diagnosis of anorexia nervosa
    • Developing targeted nutritional programs to support recovery in anorexia nervosa patients
  • Market Challenges
    • Limited effective treatment options for anorexia nervosa hinder widespread recovery

Porter's Five Forces: A Strategic Tool for Navigating the Anorexia Nervosa Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anorexia Nervosa Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anorexia Nervosa Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anorexia Nervosa Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anorexia Nervosa Market

A detailed market share analysis in the Anorexia Nervosa Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anorexia Nervosa Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anorexia Nervosa Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anorexia Nervosa Market

A strategic analysis of the Anorexia Nervosa Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anorexia Nervosa Market, highlighting leading vendors and their innovative profiles. These include Alkermes plc, Amgen Inc., Biohaven Pharmaceuticals, Hologic, Inc., Johnson & Johnson, Merck & Co., Inc., Mindstrong Health, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., PsychoGenics Inc., Sanofi S.A., Sumitomo Pharma America, Inc., Takeda Pharmaceutical Company Limited., and Tonix Pharmaceuticals Holding Corp..

Market Segmentation & Coverage

This research report categorizes the Anorexia Nervosa Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Nutritional Counseling, Pharmacotherapy, and Psychotherapy. The Pharmacotherapy is further studied across Antidepressants, Antipsychotics, and Mood Stabilizers. The Psychotherapy is further studied across Cognitive Behavioral Therapy, Family-Based Therapy, and Interpersonal Psychotherapy.
  • Based on Age Group, market is studied across Adults and Children & Adolescents.
  • Based on Severity Level, market is studied across Mild, Moderate, and Severe.
  • Based on End User, market is studied across Clinics, Homecare, and Hospitals.
  • Based on Treatment Channel, market is studied across In-Patient and Out-Patient.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expanding role of online and digital therapies in treating patients with Anorexia Nervosa
      • 5.1.1.2. Government initiatives and funding for mental health research and treatment programs
      • 5.1.1.3. Integration of multidisciplinary approaches involving nutritionists, psychologists, and medical doctors for comprehensive patient care
    • 5.1.2. Restraints
      • 5.1.2.1. High stigma and lack of awareness surrounding anorexia nervosa impede early diagnosis and intervention
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging artificial intelligence to improve early detection and diagnosis of anorexia nervosa
      • 5.1.3.2. Developing targeted nutritional programs to support recovery in anorexia nervosa patients
    • 5.1.4. Challenges
      • 5.1.4.1. Limited effective treatment options for anorexia nervosa hinder widespread recovery
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anorexia Nervosa Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Nutritional Counseling
  • 6.3. Pharmacotherapy
    • 6.3.1. Antidepressants
    • 6.3.2. Antipsychotics
    • 6.3.3. Mood Stabilizers
  • 6.4. Psychotherapy
    • 6.4.1. Cognitive Behavioral Therapy
    • 6.4.2. Family-Based Therapy
    • 6.4.3. Interpersonal Psychotherapy

7. Anorexia Nervosa Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Children & Adolescents

8. Anorexia Nervosa Market, by Severity Level

  • 8.1. Introduction
  • 8.2. Mild
  • 8.3. Moderate
  • 8.4. Severe

9. Anorexia Nervosa Market, by End User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Homecare
  • 9.4. Hospitals

10. Anorexia Nervosa Market, by Treatment Channel

  • 10.1. Introduction
  • 10.2. In-Patient
  • 10.3. Out-Patient

11. Americas Anorexia Nervosa Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Anorexia Nervosa Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Anorexia Nervosa Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. A new EUR 2.7 million research initiative explores eating disorders, self-harm, and autism links to improve early diagnosis and interventions among youth
    • 14.3.2. Equip secures additional funding to expand virtual eating disorder treatment services
    • 14.3.3. UC San Diego launches clinical trial with USD 235,000 donation to explore ketogenic therapy effectiveness on anorexia nervosa relapse prevention
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Merck & Co., Inc.

Companies Mentioned

  • 1. Alkermes plc
  • 2. Amgen Inc.
  • 3. Biohaven Pharmaceuticals
  • 4. Hologic, Inc.
  • 5. Johnson & Johnson
  • 6. Merck & Co., Inc.
  • 7. Mindstrong Health
  • 8. Otsuka Pharmaceutical Co., Ltd.
  • 9. Pfizer Inc.
  • 10. PsychoGenics Inc.
  • 11. Sanofi S.A.
  • 12. Sumitomo Pharma America, Inc.
  • 13. Takeda Pharmaceutical Company Limited.
  • 14. Tonix Pharmaceuticals Holding Corp.

LIST OF FIGURES

  • FIGURE 1. ANOREXIA NERVOSA MARKET RESEARCH PROCESS
  • FIGURE 2. ANOREXIA NERVOSA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANOREXIA NERVOSA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANOREXIA NERVOSA MARKET DYNAMICS
  • TABLE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY IN-PATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY OUT-PATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 177. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. ITALY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. ITALY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 247. POLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. POLAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. QATAR ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. QATAR ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 261. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 282. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 289. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 296. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 298. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 303. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 305. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 310. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 312. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 324. ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 325. ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2023